Trial Profile
RadVax for Relapsed/Refractory Hodgkin's Lymphoma: A Phase II Trial of Nivolumab + Low Dose Radiotherapy for Incomplete Responders
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 21 Jan 2024
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 13 Dec 2022 Protocol of study has been amended to include patients already on nivolumab if their pre-enrollment PET/CT showed failure to achieve CR
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 20 May 2022 Status changed from recruiting to discontinued.